logo

For the Inventor, By the Inventor

Middleton, WI, United States of America

Teng Ai

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Arrowhead Pharmaceuticals, Inc.. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Teng Ai. Retrieved from https://idiyas.com/inventor/teng-ai-4pa2mhzc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:

goldMedal1 out of 102 
 
Arrowhead Pharmaceuticals, Inc.
 patents

Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents
1. 11845937 - RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use (2023-12-19),

Title: The Innovations of Teng Ai in RNAi Technology

Introduction

Teng Ai is an accomplished inventor based in Middleton, WI (US), known for his significant contributions to the field of RNA interference (RNAi) technology. His work focuses on developing innovative solutions for inhibiting the expression of the DUX4 gene, which is associated with various skeletal muscle-related diseases.

Latest Patents

Teng Ai holds a patent for "RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use." This patent describes RNAi agents and compositions that include these agents, aimed at inhibiting the expression of the double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and their conjugates are designed to effectively reduce DUX4 gene expression, providing potential therapeutic benefits for individuals suffering from conditions such as Facioscapulohumeral Muscular Dystrophy (FSHD).

Career Highlights

Teng Ai is currently employed at Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technology. His innovative approaches have the potential to transform treatment options for patients with skeletal muscle disorders.

Collaborations

Teng Ai collaborates with notable colleagues, including Zhi-Ming Ding and Jonathan Van Dyke, to further enhance the impact of their research in the field of RNAi.

Conclusion

Teng Ai's work in RNAi technology represents a significant advancement in the treatment of skeletal muscle-related diseases. His innovative patent and ongoing research at Arrowhead Pharmaceuticals, Inc. highlight his commitment to improving therapeutic options for affected individuals.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…